Bentham Science Logo

Technology Transfer and Entrepreneurship

Volume 6, 2 Issues, 2019
ISSN: 2213-8102 (Online)
ISSN: 2213-8099 (Print)
This journal supports open access

Editorial Policies

For journals, the following publication policies are applied by Bentham Science.

Peer Review

Bentham Science Publishers follows the single blind peer-review procedure for submissions of all manuscripts to its journals, except for a selected number of patent journals where double blind review is followed.

All submitted articles are subjected to an extensive peer review in consultation with members of the journal’s editorial board and independent external referees (usually three reviewers). All manuscripts/chapters are assessed rapidly and the decision based on all the peer reviewers' comments, taken by the journal’s Editor-in-Chief, is then conveyed to the author(s).

Submissions from the Editor-in-Chief will undergo independent peer-review and will be submitted to another Editor for his decision on acceptance.

Copyediting and Proofs

Articles must be written in good English in a clear and correct style in order to maintain uniformity throughout the text. Articles submitted are copyedited before they are published.

Reprints

High-quality, bound/unbound, print/e-prints can be purchased for all published articles.

Copyright Letter

Articles/chapters must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The principal/corresponding author will be required to submit a Copyright Letter along with the manuscript, on behalf of all the co-authors (if any). The author(s) will confirm that the manuscript (or any part of it) has not been published previously or is not under consideration for publication elsewhere. Furthermore, any illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained.

Appeals and Complaints

Generally, the editorial decisions are not reverted. However, authors who think that their manuscript was rejected due to a misunderstanding or mistake may seek an explanation for the decision. Appeals must give sound reasoning and compelling evidence against the criticism raised in the rejection letter. A difference of opinion as to the interest, novelty, or suitability of the manuscript for the journal will not be considered as an appeal. The EIC and other relevant editors will consider the appeal and the decision thereafter taken by the journal will be deemed final. Acceptance of the manuscript is not guaranteed even if the journal agrees to reconsider the manuscript, and the reconsideration process may involve previous or new reviewers or editors and substantive revision.

Authors who wish to make a complaint should refer them to the Editor-in-Chief of the journal concerned. Complaints to the Publisher may be emailed to info@benthamscience.net

Conflict of Interest

Financial contributions and any potential conflict of interest must be clearly acknowledged under the heading ‘Conflict of Interest’. Authors must list the source(s) of funding for the study. This should be done for each author.

Plagiarism Prevention

Bentham Science uses the iThenticate software to detect instances of overlapping and similar text in submitted manuscripts. iThenticate software checks content against a database of periodicals, the Internet, and a comprehensive article database. It generates a similarity report, highlighting the percentage of overlap between the uploaded article and the published material. Any instance of content overlap is further scrutinized for suspected plagiarism according to the publisher’s Editorial Policies. Bentham Science allows an overall similarity of 20% for a manuscript to be considered for publication. The similarity percentage is further checked keeping the following important points in view

Low Text Similarity:

The text of every submitted manuscript is checked using the Content Tracking mode in iThenticate. The Content Tracking mode ensures that manuscripts with an overall low percentage similarity (but may have a higher similarity from a single source) are not overlooked. The acceptable limit for similarity of text from a single source is 5%. If the similarity level is above 5%, the manuscript is returned to the author for paraphrasing the text and citing the original source of the copied material.

It is important to mention that the text taken from different sources with an overall low similarity percentage will be considered as a plagiarized content if the majority of the article is a combination of copied material.

High Text Similarity

There may be some manuscripts with an overall low similarity percentage, but a higher percentage from a single source. A manuscript may have less than 20% overall similarity but there may be 15% similar text taken from a single article. The similarity index in such cases is higher than the approved limit for a single source. Authors are advised to thoroughly rephrase the similar text and properly cite the original source to avoid plagiarism and copyright violation.

Types of Plagiarism

We all know that scholarly manuscripts are written after thorough review of previously published articles. It is therefore not easy to draw a clear boundary between legitimate representation and plagiarism. However, the following important features can assist in identifying different kinds of plagiarized content. These are:

  • Reproduction of others words, sentences, ideas or findings as one’s own without proper acknowledgement.
  • Text recycling, also known as self-plagiarism. It is an author’s use of a previous publication in another paper without proper citation and acknowledgement of the original source.
  • Poor paraphrasing: Copying complete paragraphs and modifying a few words without changing the structure of original sentences or changing the sentence structure but not the words.
  • Verbatim copying of text without putting quotation marks and not acknowledging the work of the original author.
  • Properly citing a work but poorly paraphrasing the original text is considered as unintentional plagiarism. Similarly, manuscripts with language somewhere between paraphrasing and quoting are not acceptable. Authors should either paraphrase properly or quote and in both cases, cite the original source.
  • Higher similarity in the abstract, introduction, materials and methods, and discussion and conclusion sections indicates that the manuscript may contain plagiarized text. Authors can easily explain these parts of the manuscript in many ways. However, technical terms and sometimes standard procedures cannot be rephrased; therefore Editors must review these sections carefully before making a decision.

Plagiarism in Published Manuscripts

Published manuscripts which are found to contain plagiarized text are retracted from the journal’s website after careful investigation and approval by the Editor-in-Chief of the journal. A ‘Retraction Note’ as well as a link to the original article is published on the electronic version of the plagiarized manuscript and an addendum with retraction notification in the particular journal.

Copyright and License

Open Access Plus (Subscription Journals)

Accepted articles can be published online for free open access. Open access publishing provides maximum dissemination of the article to the largest audience. All authors will be asked to indicate whether or not they wish to pay to have their paper made freely available on publication. If authors do not select the 'Open Access Plus' option, then their article will be published with standard subscription-based access.

Copyright (Subscription Journals)

Editors/Authors who contribute in a Bentham’s Journal will transfer copyright to their work to Bentham Science Publishers. Submission of a manuscript to the respective journals implies that all editors/authors have read and agreed to the content of the copyright letter.

HUMAN AND ANIMAL RIGHTS

All clinical investigations should be conducted according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee are required.

For research involving animals, the authors should indicate whether the procedures followed were in accordance with the standards set forth in the eighth edition of “Guide for the Care and Use of Laboratory Animals” (grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).

Research Involving Animals

Research work on animals should be carried out in accordance with the NC3Rs ARRIVE Guidelines. For In Vivo Experiments, please visit https://www.nc3rs.org.uk/arrive-guidelines

Authors should clearly state the name of the approval committee, highlighting that legal and ethical approvals were obtained prior to initiation of the research work carried out on animals, and that the experiments were performed in accordance with the relevant guidelines and regulations stated below.

Research Involving Plants

All experimental research on plants (either cultivated or wild), should comply with international guidelines. The manuscript should include a declaration of compliance of field studies with relevant guidelines and/or relevant permissions or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

Patient Consent

Compliance with the guidelines of the International Committee of Medical Journal Editors www.icmje.org) is recommended, in accordance with the patient’s consent for research or participation in a study as per the applicable laws and regulations regarding the privacy and/or security of personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and other U.S. federal and state laws relating to confidentiality and security of personally distinguishable evidence, the General Data Protection Regulation (GDPR) (EU) 2016/679 and member state implementing legislation, Canada's Personal Information Protection and Electronic Documents Act, India's Information Technology Act and related Privacy Rules, (together "Data Protection and Privacy Laws").

It is the responsibility of the author to ensure that:

  • Patients' names, initials, or hospital numbers are not mentioned anywhere in the manuscript (including figures).
  • Authors are responsible for obtaining the patient consent-to-disclose forms for all recognizable patients in photographs, videos, or other information that may be published in the Journal, in derivative works, or on the journal’s web site and for providing the manuscript to the recognizable patient for review before submission.
  • The consent-to-disclose form should indicate specific use (publication in the medical literature in print and online, with the understanding that patients and the public will have access) of the patient's information and any images in figures or videos, and must contain the patient's signature or that of a legal guardian along with a statement that the patient or legal guardian has been offered the opportunity to review the identifying materials and the accompanying manuscript.
  • If the manuscript has an individuals’ data, such as personal details, audio-video material, etc., consent should be obtained from that individual. In case of children, consent should be obtained from the parent or the legal guardian.
  • A specific declaration of such approval and consent-to-disclose form must be made in the copyright letter and in a stand-alone paragraph at the end of the article especially in the case of human studies where inclusion of a statement regarding obtaining the written informed consent from each subject or subject's guardian is a must. The original should be retained by the guarantor or the corresponding author. Editors may request to provide the original forms by fax or email.
  • All such case reports require by a proper consent being obtained prior to publishing.

Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study. The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.

Non-identifiable Images

Anonymous images, that do not identify the individual directly or indirectly, such as through any identifying marks or text, do not require formal consent, for example, X-rays, ultrasound images, pathology slides or laparoscopic images.

In case consent is not obtained, concealing the identity through eye bars or blurring the face would not be acceptable.

UNETHICAL BEHAVIOR

Unethical behavior and misconduct may be pointed out by anyone to the Editor and Publisher with sufficient evidences. The Editor, in consultation with the Publisher, will initiate investigation against this Unethical misconduct, complete the procedure till an unbiased decision is reached, and maintain confidentiality throughout the process of the investigation. The Author should be given the opportunity to reply to all minor or major accusations.

In case of serious breaches, the employer may be informed where appropriate, by the Editor/Publisher, after reviewing all available information and evidences or after seeking help from experts in that field.

Conclusion

  • Author(s) and Reviewers must be informed in case of misinterpretation or mishandling of International Acceptable Standards
  • A strict notice should be sent to the author and reviewer to avoid future unethical misconduct
  • An Editorial on the reported misconduct should be published or official notice of unethical behavior should be posted on the website
  • Official letter about this misconduct should be issued to the Head of Departments, Funding Agencies of the accused author and the reviewer, as well as Abstracting & Indexing Agencies.
  • Where required, retraction and withdrawal of publication may be undertaken from the Publisher’s journal in discussion with the Head of the Department of the author or reviewer, and other higher authorities should be informed
  • The Publisher may impose restrictions for some period on future publications from the accused author in the journals

Errata and Corrections in Published Articles

Authors and readers are encouraged to notify the Editor-in-Chief if they find errors in published content, authors’ names and affiliations or if they have reasons for concern over the legitimacy of a publication. In such cases the journal will publish an ERRATUM or a CORRIGENDUM, in consultation with Editor-in-Chief and authors of the article, and/or replace or retract the article.

Article Withdrawal

Articles in Press (articles that have been accepted for publication or published as E-pub Ahead of Schedule but which have not been formally published with volume/issue/page information) that include errors, or are determined to violate the publishing ethics guidelines such as multiple submission, fake claims of authorship, plagiarism, fraudulent use of data or the like, may be “Withdrawn” from the journal. Withdrawal means that the article files are removed and replaced with a PDF stating that the article has been withdrawn from the journal in accordance with BSP Editorial Policies.

Article Retraction

Published articles (with volume/issue/page information) which may contain infringements of professional ethical codes, such as multiple submissions, bogus claims of authorship, plagiarism, fraudulent use of data or the like are retracted.

  • A retraction note titled “Retraction: [article title]” signed by the authors and/or the Editor-in-Chief is published in the paginated part of a subsequent issue of the journal and listed in the contents list.
  • In the electronic version, a link is made to the original article.
  • The online article is preceded by a screen containing the retraction note. It is to this screen that the link resolves; the reader can then proceed to the article itself.
  • The original article is retained unchanged with a watermark on the PDF indicating on each page that it is “retracted.”

Concurrent Publication/Simultaneous Submission

It is a condition of publication that manuscripts submitted to the Bentham journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered.

Abstracts and posters of conferences, results presented at meetings (for example, to inform investigators or participants about findings), results databases (data without interpretation, discussion, context or conclusions in the form of tables and text to describe data/information where this is not easily presented in tabular form) are not considered prior publication.

Authors who wish to publish translations of the articles that have been published elsewhere should ensure that they have appropriate permission(s), indicate clearly that the material has been translated and re-published, and indicate clearly the original source of the material. The Editor-in-Chief may request copies of related publications if he/she is concerned about overlap and possible redundancy.

PERMISSION FOR REPRODUCTION

Bentham Science has collaborated with the Copyright Clearance Center to meet its customer’s licensing, besides rights & permission needs.

The Copyright Clearance Center’s RightsLink® service makes it faster and easier to secure permission from Bentham Science journal titles. Simply visit Journals by Title and locate the desired content. Then go to the article’s abstract and click on “Rights and Permissions” to open the RightsLink’s page. If you are unable to locate the content you wish to use or are unable to secure the rights you are seeking, please e-mail us at permissions@benthamscience.net

Published/reproduced material should not be included unless written permission has been obtained from the copyright holder, which should be forwarded to the Editorial Office in case of acceptance of the article for publication.

Disclaimer

Responsibility for the content published by Bentham Science Publishers in any of its journals, including any opinions expressed therein, rests exclusively with the author(s) of such content. To the maximum extent permitted by applicable law, BSP (on its own behalf, and on behalf of its staff and members of its editorial board) disclaims responsibility for any and all injury and/or damage (whether financial or otherwise) to persons or property, resulting directly or indirectly from any ideas, methods, instructions or products (including errors in the same) referred to in the content of any of BSP’s journals. Any dispute arising, including any claim shall be governed exclusively by the laws of the United Arab Emirates, as applied in the Emirate of Sharjah.


Co-Editors tte_ce_DMGross_001 Gross Dennis M. Pennsylvania Drug Discovery Institute Doylestown PA USA Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute. tte_ce_CEBeyer_003 Beyer Chad E. Promentis Pharmaceuticals Milwaukee WI USA Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science. Founding Editor tte_ce_ABReitz_002 Reitz A.B. Pennsylvania Drug Discovery Institute Doylestown PA USA Dr. Reitz obtained a doctorate (Ph.D.) in Chemistry from the University of California, San Diego. Dr. Reitz also holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering). Currently Dr. Reitz is also an Adjunct Professor in the Drexel University College of Medicine. He has published more than 150 scientific publications and is a named inventor of 60 issued U.S patents. Dr. Reitz was the founding Editor (2000) and is currently the Editor-in-Chief of this journal (Current Topics in Medicinal Chemistry, CTMC), published by Bentham Science Publishers. Associate Editors tte_ebm_steinman_031 Steinman H.A. The Wistar Institute Philadelphia PA USA Dr. Steinman holds a doctorate in biomedical sciences from the University of Massachusetts Medical School and an MBA from the university’s Isenberg School of Management. She graduated Summa Cum Laude from Baldwin-Wallace College with dual degrees in biology and psychology in the honors program. Heather Steinman, Ph.D., MBA, is Vice President for Business Development and Executive Director of Technology Transfer at The Wistar Institute, the nation’s first independent research institution devoted solely to biomedical science and a world leader in cancer, immunology, virology and infectious disease research. Dr. Steinman brings more than 18 years of experience in technology transfer and commercialization of early stage-life science discoveries. tte_ae_NLVanderford_001 Vanderford N.L. University of Kentucky Lexington KY USA Dr. Vanderford received a doctorate (Ph.D.) in Biochemistry from the University of Kentucky and he also holds a Master of Business Administration (MBA) degree. Dr. Vanderford holds a number of positions at the University of Kentucky including: Assistant Professor in the Department of Toxicology and Cancer Biology; Instructor in the Graduate School; Assistant Dean for Academic Development in the College of Medicine; and the Assistant Director for Research for the Markey Cancer Center. He has published his work in a number of prestigious journals including Science, Nature, and Nature Biotechnology. In addition to serving as Associate Editor for Technology Transfer and Entrepreneurship, he is also the Deputy Editor for the Journal of Research Administration. Section Editors tte_se_Gunn_001 Gunn M.A. University of San Francisco San Francisco CA USA Dr. Moira Gunn is an Associate Professor at University of San Francisco. She did her MS in Computer Science and PhD in Mechanical Engineering from Purdue University, Lafayette, IN, USA. Dr. Gunn has been teaching courses at the University of San Francisco since 1979. She was the Director of Information Systems Program in USF from 2007 to 2009. She is the leader of Business of Biotechnology Program in USF School of Management. She received Educator of the Year award from EE Times in 2008. She has also received Public Service Award for contribution to the public understanding of science and engineering from National Science Board in 2011. Academic Technology Transfer tte_se_JMSilvaggi_002 Silvaggi J.M. UWM Research Foundation Milwaukee WI USA Technology Transfer Dr. Jessica Silvaggi received her Ph.D. in Biochemistry from the Department of Molecular and Cellular Biology at Harvard University, and conducted a post-doctoral fellowship at the Dana Farber Cancer Institute. She has been with the UWM Research Foundation since 2009, and is currently the Senior Licensing Manager where she evaluates new inventions, manages the patent, marketing, and licensing programs, and aids in teaching students and faculty about new start-up formation. Dr. Silvaggi became a certified licensing professional in 2014, and she enjoys growing the technology transfer program at UWMRF while helping to increase the level of entrepreneurship in Milwaukee. Editorial Board Members tte_ebm_garrison-s_001 Garrison S. Aurora Research Institute Milwaukee WI USA Dr. Garrison earned his Ph.D. in Biological Sciences - Neuroscience from the University of Wisconsin, Milwaukee (USA) before completing his postdoctoral training in sensory biology at the Medical College of Wisconsin, Milwaukee (USA). He has previously worked with successful start-up companies in drug development, biotech consulting and bioinformatics. Currently, Dr. Garrison serves as a Research Scientist for the Aurora Research Institute, Aurora Health Care, and is the Wisconsin State Leader for the National Organization for Rare Disorders (NORD). tte_ebm_EBarnhard_001 Barnhard E. Leason Ellis LLP New York NY USA ELIZABETH M. BARNHARD is Chair of the Pharma/Biotech Practice Group at Leason Ellis. With her many years of pharma industry and law firm experience, she works closely with clients to create and manage robust intellectual property portfolios that add value to their businesses. She is experienced in transactional and licensing work, in all phases of litigation and appeals of patent, trademark, copyright and unfair competition actions, and in patentability, freedom-to-operate, infringement, validity, product and manufacturing patent clearances in the areas of oncology/immunology, infectious diseases, virology, central nervous system disorders, cardiovascular/metabolic disorders, and molecular genetics. tte_ebm_barrett-je_002 Barrett J.E. Drexel University College of Medicine Philadelphia PA USA Dr. James E. Barrett, Professor in the Department of Neurology, Pharmacology and Physiology and former Chair, Drexel University College of Medicine. He received his Ph.D. from Pennsylvania State University with postdoctoral training in neuropsychopharmacology at the Worcester Foundation for Experimental Biology. Dr. Barrett was Vice President of Neuroscience Discovery Research at Wyeth, Senior Vice President and Chief Scientific Officer, Adolor Corporation and Memory Pharmaceuticals. He has received several awards for significant contributions to pharmacology. He is a member of the Executive Committee of the IUPHAR. His current research emphasis is on pain and the development of novel therapeutics. tte_ebm_MGBerenstein_003 Berenstein M.G Dirección de Vinculación Tecnológica - CONICET Buenos Aires Argentina Dr Berenstein is Advisor to Vicepresident from CONICET and independent consultant in Technology transfer and Biobusiness for Scientific Community, Industry and Investment groups.. With more than 20 years of experience both in Research and tecnology transfer, she also held Management level positions in both public institutions and private companies in the Life Science Industry. She was previously ViceDirector, General Manager, and Director of leading Offices of Technology transfer and Bioincubators in Argentina (CONICET and Instituto Leloir) . Dr Berenstein holds a PhD in Gene therapy from University of Buenos Aires and an MBA from University of San Andrés. She is also Academic Director and Professor of Postgraduates courses in Pharma and Biotechnology Business from leading business Universities in Argentina. tte_ebm_AKChakraborti_005 Chakraborti A.K. National Institute of Pharmaceutical Education and Research Mohali India Dr. Asit K. Chakraborti is Professor and Head of the Department of Medicinal Chemistry, NIPER, S. A. S. Nagar, Punjab, India. He received Ph. D. degree in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science (IACS), Kolkata, India. He has published 166 research papers (with > 7600 citation and h index of 51) and filed 42 patents. He received several awards and recognition such as University Gold Medal, Bardhaman Sammilani Gold Medal, ISMAS Eminent Mass-spectroscopist Award, etc. He is the Fellow of the Royal Society of Chemistry and Indian Science Academies. tte_ebm_cullis_009 Cullis C. Case Western Reserve University Cleveland OH USA Dr. Cullis is the Francis Hobart Herrick Professor of Biology at Case Western Reserve University and Director of the Biotechnology Entrepreneurship Master’s Program. He is currently President of the Society for Bioentrepreneurship Education and Research (SIBER). His research has focused primarily on rapid genomic variation in plants. He is also currently working on developing a wild legume (marama, Tylosema esculentum) into a crop for resource poor farmers in Southern Africa. He has served as a program director at the National Science Foundation, on grant review panels, advisory and on editorial advisory boards of multiple journals. tte_ebm_KJDakin_009 Dakin K.J. Dakin Capital Services Centennial CO USA Karl Dakin has 38 years in innovation commercialization. Mr. Dakin is a respected educator, extraordinary communicator, visionary leader with an entrepreneurial spirit and a small business advocate. Mr. Dakin is engaged in multiple new product, business and economic development projects. At the crossroads of capital and food, he is leading the development of a new democratized capital ecosystem within the State of Colorado where everyone can invest in Main Street businesses and he is increasing local food production by development, sale and operation of turnkey indoor agriculture systems. tte_ebm_Lawton_001 Lawton D. Promentis Pharmaceuticals Milwaukee WI USA Daniel is President of Promentis Pharmaceuticals, Inc., a biopharma company developing new therapies for the treatment of CNS disorders. Daniel was previously Group President at Dohmen, where he led five Dohmen group companies in the life science services space. Daniel was General Counsel of Schwarz Pharma Inc. and previously at Abbott Laboratories where he was Senior Counsel to both the domestic and international organizations. Daniel is a graduate of the University of Michigan and Harvard Law School, and was a Teaching Fellow in economics at Harvard College. tte_ebm_NOssanna_022 Ossanna N. University of Arizona Tucson AZ USA Nina Ossanna, PhD holds a PhD in Molecular Biology and is a registered US patent agent. She is a founder and VP Business Development for Pharos Diagnostics and owner of Sonora Bioconsulting. She also Chairs the Bioindustry Organization of Southern Arizona. She has worked in university tech transfer directing offices at Johns Hopkins Medical School and the University of Arizona as well as working in start-up life science companies. tte_ebm_FOzsolak_023 Ozsolak F. RaNA Therapeutics Cambridge MA USA Dr. Ozsolak is an Associate Director at Vertex Pharmaceuticals. He previously worked at Biogen and RaNA Therapeutics, contributing to the discovery and development of drugs to treat CNS, liver and kidney diseases via small molecule and oligotherapeutics approaches. He obtained his PhD in biological chemistry and molecular pharmacology from Harvard University, and BA in biochemistry from Washington University in St. Louis. tte_ebm_schoen_001 Schoen F.J. Harvard Medical School Boston MA USA Frederick J. Schoen, M.D., Ph.D., is Professor of Pathology and Health Sciences and Technology (HST) at Harvard Medical School, and Executive Vice-Chairman of the Department of Pathology at Brigham and Women's Hospital (BWH). His research focuses on native and substitute heart valves. In institutional roles, he promotes multidisciplinary innovation using technology, provides mentoring and career development leadership for translational research, and teaches Pathology, Biomaterials, Tissue Engineering and Medical Device Development. He serves on the Massachusetts Life Sciences Center SAB, and many academic and governmental advisory, grant review and editorial committees, and consults with medical device companies. tte_ebm_s-m-stahl_001 Stahl S.M. University of California Oakland CA USA Dr. Stahl obtained his MD from Northwestern University, his PhD in pharmacology from the University of Chicago and his postdoctoral trainin in Internal Medicine from the University of Chicago, in Neurology from the University of California San Francisco and in Psychiatry from Stanford University. Currently Dr. Stahl is a professor of psychiatry at the University of California San Diego and an Honorary Fellow at the University of Cambridge (UK). He serves as editor-in-chief of CNS Spectrums and is director of psychopharmacology for the California Department of State Hospitals. Author of over 500 papers, 35 textbooks and 12 edited books, Dr. Stahl is an internationally recognized expert in psychopharmacology. tte_ebm_JETetzlaff_032 Tetzlaff J.E. Medical College of Wisconsin Milwaukee WI USA Dr. Tezlaff did her B.A. from University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Ph.D. from Loyola University Chicago, Maywood, IL, USA; and Postdoctorate from Massachusetts General Hospital of the Harvard Medical School, Boston, MA, USA. She worked as a scientist at Seaside Therapeutics, Cambridge, MA from 2008 till 2011. In 2011, she joined Department of Pathology of the Medical College of Wisconsin and has been working there as an Assistant Professor since then. She has also been serving as the Assistant Dean of Postdoctoral Education at the Medical College of Wisconsin since 2014. Her research interest includes Sudden Infant Death Syndrome, Infant Mortality, Neuroscience, Biomarkers, Professional and career development and Entrepreneurial initiatives. tte_ebm_tobet_001 Tobet S. Colorado State University Fort Collins CO USA Dr. Tobet obtained a master’s degree (S.M.) and doctorate (Ph.D.) in Applied Biological Sciences from the Massachusetts Institute of Technology in Cambridge, MA. After 14 years in Boston as faculty at Harvard Medical School and then University of Massachusetts Medical School, he moved to Colorado State University (CSU) as a Professor in the College of Veterinary Medicine and Biomedical Sciences in 2003. In 2010 he was named the Director of the CSU School of Biomedical Engineering. He has published more than 135 papers in scientific journals. At CSU he helped create and deliver courses in Biomedical Entrepreneurship, Grant Writing, and STEM Communication.

Journal History

Technology Transfer and Entrepreneurship Journal was launched in 2014. Dr. Dennis M. Gross and Dr. Chad E. Beyer are the Co- Editors of the journal.
Track Your Manuscript:



Related Journals

Related eBooks

eBooks Catalog